title: Study of the inferior colliculus in patients with schizophrenia by magnetic resonance spectroscopy.
abstract: INTRODUCTION. Previous studies have suggested morphometric and functional abnormalities in the inferior colliculus in patients with schizophrenia. Auditory hallucinations are one of the central symptoms in schizophrenia. In this complex and multidimensional event both attention and emotion are thought to play a key role. AIM. To study metabolic changes in the inferior colliculus, a nucleus integrated in the auditory pathway, in patients with schizophrenia and the possible relationship with auditory hallucinations. SUBJECTS AND METHODS. Magnetic resonance spectroscopic imaging studies were performed in 30 right-handed patients with chronic schizophrenia (19 of them with auditory hallucinations) and 28 controls. A magnetic resonance spectroscopic imaging 2D slice was acquired and the voxels representative of both inferior colliculi were selected. N-acetylaspartate (NAA), creatine (Cr) and choline (Cho) peak areas were measured. RESULTS. The patients with schizophrenia showed a NAA/Cr significant reduction in the right inferior colliculus compared to the control subjects. The metabolic data in the right inferior colliculus were correlated with emotional auditory hallucinations items. CONCLUSIONS. The contribution of the inferior colliculus on neural underpinnings of auditory hallucinations is particularly relevant for the right inferior colliculus and is centered on attention-emotional component of this symptom.
authors: B
authors: B
authors: Martinez-Granados
authors: M C
authors: MC
authors: Martinez-Bisbal
authors: J
authors: J
authors: Sanjuan
authors: E J
authors: EJ
authors: Aguilar
authors: L
authors: L
authors: Marti-Bonmati
authors: E
authors: E
authors: Molla
authors: Universidad de Valencia. Facultad de Quimica, 46100 Burjassot, Espana.
authors: B
authors: B
authors: Celda
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000032:analysis; D002746:Chlorpromazine / Q000627:therapeutic use; D002794:Choline / Q000032:analysis; D003401:Creatine / Q000032:analysis; D005260:Female; D006212:Hallucinations / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007245:Inferior Colliculi / Q000737:chemistry* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019906:Nuclear Magnetic Resonance, Biomolecular; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
chemical_list: D014150:Antipsychotic Agents; D001224:Aspartic Acid; C000179:N-acetylaspartate; D003401:Creatine; D002794:Choline; D002746:Chlorpromazine